Eshmuminov, Dilmurodjon
Aminjonov, Botirjon
Palm, Russell F.
Malleo, Giuseppe
Schmocker, Ryan K.
Abdallah, Raëf
Yoo, Changhoon
Shaib, Walid L.
Schneider, Marcel André
Rangelova, Elena
Choi, Yoo Jin
Kim, Hongbeom
Rose, J. Bart
Patel, Sameer
Wilson, Gregory C.
Maloney, Sarah
Timmermann, Lea
Sahora, Klaus
Rössler, Fabian
Lopez-Lopez, Víctor
Boyer, Emanuel
Maggino, Laura
Malinka, Thomas
Park, Jeong Youp
Katz, Matthew H. G.
Prakash, Laura
Ahmad, Syed A.
Helton, Scott
Jang, Jin-Young
Hoffe, Sarah E.
Salvia, Roberto
Taieb, Julien
He, Jin
Clavien, Pierre-Alain
Held, Ulrike
Lehmann, Kuno
Funding for this research was provided by:
University of Zurich
Article History
Received: 1 November 2022
Accepted: 1 March 2023
First Online: 5 April 2023
Disclosures
: Sarah Hoffe: Galera Pharmaceuticals, Institutional Principal Investigator for the GRECO-2 randomized international study for which my cancer center receives funding to support the trial, it is a pancreas trial that includes SBRT. D.E., B.A., R.P share first authorship.